Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Vitamins
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PAPILLON
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 01 Nov 2025 The subpopulation analysis of Japanese population(n=34) evaluating amivantamab in combination with chemotherapy, versus chemotherapy alone published in the Cancer Science.
  • 24 Sep 2024 According to a Johnson & Johnson media release, company announced that it has received manufacturing and marketing approval in Japan for Livelivant. This approval is based on results from the Phase 3 PAPILLON trial.
  • 03 Jul 2024 According to a Johnson & Johnson media release, based on results from this trial Health Canada, through a Priority Review, has issued a Notice of Compliance for RYBREVANT(amivantamab) in combination with platinum-based chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor Exon 20 insertion mutations.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top